Latest News | Glenmark Launches Triple-drug Combo for Type 2 Diabetes

New Delhi, Oct 18 (PTI) Glenmark Pharmaceuticals on Wednesday said it has launched a triple-fixed-dose combination (FDC) drug for treatment of diabetes.

The Mumbai-based drug firm has introduced the combination of Teneligliptin, Dapagliflozin and Metformin under the brand name Zita.

Also Read | Madhya Pradesh Assembly Election 2023: Congress Releases Manifesto; Promises Rs 25 Lakh Health Insurance Cover, 27% OBC Quota (See Pics and Video).

It is indicated to improve glycemic control in patients with Type 2 diabetes.

Priced at Rs 14 per tablet (per day), the medication lowers the daily cost of therapy by 30 per cent; making it affordable for the patients, the drug firm stated.

Also Read | What Is APAAR Card? Know All About Unique Identity Cards To Be Rolled Out for Students as Part of ‘One Nation, One ID’ Plan to Track Their Academic Progress.

Glenmark Pharma President & Business Head (India Formulations) Alok Malik said the drug helps improve the glycemic control among adult patients with high HbA1c and other co-morbidities; while also reducing major renal and cardiac adverse events.

According to IQVIA sales data for the 12-month period ending August 2023, the market for oral anti-diabetic drugs in India is estimated at Rs 12,522 crore, with an annual growth of 6.5 per cent against the corresponding period last year.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)